Recently, it was shown that the overproduction of HER2-SHCBP1-PLK1 diminishes the efficacy of trastuzumab in the treatment of HER2-positive gastric cancer by promoting tumor cell mitosis [38]. The gene discussed is SHCBP1; the disease is gastric cancer.